ProQR Therapeutics N.V.

SecurityPRQR / ProQR Therapeutics N.V.
InstitutionCitadel Advisors Llc
ManagerKen Griffin
Latest Disclosed Ownership703,323 shares
Latest Disclosed Value $ 1,139,383
Citadel Advisors Llc ownership in PRQR / ProQR Therapeutics N.V.

On May 15, 2026 - Citadel Advisors Llc filed a 13F-HR form disclosing ownership of 703,323 shares of ProQR Therapeutics N.V. (US:PRQR) valued at $1,139,383 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 583,222 shares of ProQR Therapeutics N.V.. This represents a change in shares of 20.59% during the quarter. The current value of the position is $1,054,984 USD.

Citadel Advisors Llc has a history of taking positions in derivatives of the underlying security (PRQR) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

PRQR / ProQR Therapeutics N.V. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F PROQR THRAPEUTICS N V SHS EURO N71542109 703,323 120,101 20.59 1,139 -3.31 0.0002
2026-02-17 2025-12-31 13F PROQR THRAPEUTICS N V SHS EURO N71542109 583,222 -73,790 -11.23 1,178 -15.80 0.0002
2025-11-14 2025-09-30 13F PROQR THRAPEUTICS N V SHS EURO N71542109 657,012 277,749 73.23 1,399 80.98 0.0002
2025-08-14 2025-06-30 13F PROQR THRAPEUTICS N V SHS EURO N71542109 379,263 -439,595 -53.68 774 -29.02 0.0001
2025-05-15 2025-03-31 13F PROQR THRAPEUTICS N V SHS EURO N71542109 818,858 410,051 100.30 1,089 0.55 0.0002
2025-02-14 2024-12-31 13F PROQR THRAPEUTICS N V SHS EURO N71542109 408,807 321,830 370.02 1,083 585.44 0.0002
2024-11-14 2024-09-30 13F PROQR THRAPEUTICS N V SHS EURO N71542109 86,977 68,612 373.60 158 426.67 0.0000
2024-08-14 2024-06-30 13F PROQR THRAPEUTICS N V SHS EURO N71542109 18,365 -27,643 -60.08 30 -71.15 0.0000
2024-05-15 2024-03-31 13F PROQR THRAPEUTICS N V SHS EURO N71542109 46,008 -31,808 -40.88 104 -32.47 0.0000
2024-02-14 2023-12-31 13F PROQR THRAPEUTICS N V SHS EURO N71542109 77,816 77,816 154 0.0000
2023-11-14 2023-09-30 13F PROQR THRAPEUTICS N V SHS EURO N71542109 0 -116,792 -100.00 0 -100.00
2023-08-14 2023-06-30 13F PROQR THRAPEUTICS N V SHS EURO N71542109 116,792 17,013 17.05 189 -10.85 0.0000
2023-05-15 2023-03-31 13F PROQR THRAPEUTICS N V SHS EURO N71542109 99,779 99,779 213 0.0000
2022-11-14 2022-09-30 13F PROQR THRAPEUTICS N V SHS EURO N71542109 0 -209,215 -100.00 0 -100.00
2022-08-15 2022-06-30 13F PROQR THRAPEUTICS N V SHS EURO N71542109 209,215 209,215 162 0.0000
2022-05-16 2022-03-31 13F PROQR THRAPEUTICS N V SHS EURO N71542109 0 -222,269 -100.00 0 -100.00
2022-02-14 2021-12-31 13F PROQR THRAPEUTICS N V SHS EURO N71542109 222,269 130,063 141.06 1,781 130.70 0.0004
2021-11-15 2021-09-30 13F PROQR THRAPEUTICS N V Cmn N71542109 92,206 34,076 58.62 772 96.94 0.0002
2021-08-16 2021-06-30 13F PROQR THRAPEUTICS N V SHS EURO N71542109 58,130 29,754 104.86 392 108.51 0.0001
2021-05-21 2021-03-31 13F/A-1 PROQR THRAPEUTICS N V SHS EURO N71542109 28,376 28,376 -51.19 188 -52.04 0.0000
2021-05-17 2021-03-31 13F PROQR THRAPEUTICS N V SHS EURO N71542109 28,376 28,376 188 0.0000
2020-02-14 2019-12-31 13F PROQR THRAPEUTICS N V Cmn N71542109 0 -65,996 -100.00 0 -100.00
2019-11-14 2019-09-30 13F PROQR THRAPEUTICS N V Cmn N71542109 65,996 22,971 53.39 380 -2.81 0.0002
2019-08-14 2019-06-30 13F PROQR THRAPEUTICS N V Cmn N71542109 43,025 -39,314 -47.75 391 -65.76 0.0002
2019-05-15 2019-03-31 13F PROQR THRAPEUTICS N V Cmn N71542109 82,339 30,367 58.43 1,142 39.44 0.0006
2019-02-14 2018-12-31 13F PROQR THRAPEUTICS N V Cmn N71542109 51,972 51,972 334.55 819 695.15 0.0004
2016-05-13 2016-03-31 13F PROQR THERAPEUTICS Cmn N71542109 0 -11,960 -100.00 0 -100.00
2017-01-31 2015-12-31 13F/A-1 PROQR THRAPEUTICS N V Cmn N71542109 11,960 -1,676 -12.29 103 -47.98 0.0001
2016-02-12 2015-12-31 13F PROQR THERAPEUTICS Cmn N71542109 11,960 103
2015-11-16 2015-09-30 13F PROQR THERAPEUTICS Cmn N71542109 13,636 634 4.88 198 -8.76 0.0002
2015-08-14 2015-06-30 13F PROQR THERAPEUTICS Cmn N71542109 13,002 3,405 35.48 217 3.33 0.0002
2015-05-15 2015-03-31 13F PROQR THERAPEUTICS Cmn N71542109 9,597 9,597 -26.19 210 -3.23 0.0002
2015-02-17 2014-12-31 13F PROQR THERAPEUTICS Cmn N71542109 0 -108,715 -100.00 0 -100.00
2014-11-14 2014-09-30 13F PROQR THERAPEUTICS Cmn N71542109 108,715 108,715 1,869 0.0023
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F PROQR THRAPEUTICS N V SHS EURO Call 0 -100.00 0 -100.00 n/a n/a n/a
2026-02-17 2025-12-31 13F PROQR THRAPEUTICS N V SHS EURO Call 34,200 69 n/a n/a n/a
2025-08-14 2025-06-30 13F PROQR THRAPEUTICS N V SHS EURO Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-05-15 2025-03-31 13F PROQR THRAPEUTICS N V SHS EURO Call 3,600 -82.86 5 -92.73 n/a n/a n/a
2025-02-14 2024-12-31 13F PROQR THRAPEUTICS N V SHS EURO Call 21,000 6,900.00 56 n/a n/a n/a
2024-11-14 2024-09-30 13F PROQR THRAPEUTICS N V SHS EURO Call 300 -83.33 1 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F PROQR THRAPEUTICS N V SHS EURO Call 1,800 -95.00 3 -97.53 n/a n/a n/a
2024-05-15 2024-03-31 13F PROQR THRAPEUTICS N V SHS EURO Call 36,000 53.85 82 76.09 n/a n/a n/a
2024-02-14 2023-12-31 13F PROQR THRAPEUTICS N V SHS EURO Call 23,400 46 n/a n/a n/a
2023-11-14 2023-09-30 13F PROQR THRAPEUTICS N V SHS EURO Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-08-14 2023-06-30 13F PROQR THRAPEUTICS N V SHS EURO Call 52,900 -4.34 86 -27.35 n/a n/a n/a
2023-05-15 2023-03-31 13F PROQR THRAPEUTICS N V SHS EURO Call 55,300 189.53 118 67.14 n/a n/a n/a
2023-02-14 2022-12-31 13F PROQR THRAPEUTICS N V SHS EURO Call 19,100 -9.48 71 337.50 n/a n/a n/a
2022-11-14 2022-09-30 13F PROQR THRAPEUTICS N V SHS EURO Call 21,100 -55.30 16 -56.76 n/a n/a n/a
2022-08-15 2022-06-30 13F PROQR THRAPEUTICS N V SHS EURO Call 47,200 52.26 37 32.14 n/a n/a n/a
2022-05-16 2022-03-31 13F PROQR THRAPEUTICS N V SHS EURO Call 31,000 17.87 28 -86.73 n/a n/a n/a
2022-02-14 2021-12-31 13F PROQR THRAPEUTICS N V SHS EURO Call 26,300 -51.92 211 -53.93 n/a n/a n/a
2021-11-15 2021-09-30 13F PROQR THRAPEUTICS N V Cmn Call 54,700 82.33 458 126.73 n/a n/a n/a
2021-08-16 2021-06-30 13F PROQR THRAPEUTICS N V SHS EURO Call 30,000 -30.23 202 -28.87 n/a n/a n/a
2021-05-21 2021-03-31 13F/A PROQR THRAPEUTICS N V SHS EURO Call 43,000 43.33 284 40.59 n/a n/a n/a
2021-05-17 2021-03-31 13F PROQR THRAPEUTICS N V SHS EURO Call 43,000 284 n/a n/a n/a
2020-11-16 2020-09-30 13F PROQR THRAPEUTICS N V Cmn Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-08-14 2020-06-30 13F PROQR THRAPEUTICS N V Cmn Call 21,600 54.29 131 70.13 n/a n/a n/a
2020-05-15 2020-03-31 13F PROQR THRAPEUTICS N V Cmn Call 14,000 77 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-08-14 2025-06-30 13F PROQR THRAPEUTICS N V SHS EURO Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-05-15 2025-03-31 13F PROQR THRAPEUTICS N V SHS EURO Put 5,300 -15.87 7 -56.25 n/a n/a n/a
2025-02-14 2024-12-31 13F PROQR THRAPEUTICS N V SHS EURO Put 6,300 10.53 17 60.00 n/a n/a n/a
2024-11-14 2024-09-30 13F PROQR THRAPEUTICS N V SHS EURO Put 5,700 -33.72 10 -28.57 n/a n/a n/a
2024-08-14 2024-06-30 13F PROQR THRAPEUTICS N V SHS EURO Put 8,600 -27.12 14 -46.15 n/a n/a n/a
2024-05-15 2024-03-31 13F PROQR THRAPEUTICS N V SHS EURO Put 11,800 637.50 27 766.67 n/a n/a n/a
2024-02-14 2023-12-31 13F PROQR THRAPEUTICS N V SHS EURO Put 1,600 3 n/a n/a n/a
2023-11-14 2023-09-30 13F PROQR THRAPEUTICS N V SHS EURO Put 0 -100.00 0 -100.00 n/a n/a n/a
2023-08-14 2023-06-30 13F PROQR THRAPEUTICS N V SHS EURO Put 13,900 -77.83 23 -83.46 n/a n/a n/a
2023-05-15 2023-03-31 13F PROQR THRAPEUTICS N V SHS EURO Put 62,700 -23.91 134 -56.25 n/a n/a n/a
2023-02-14 2022-12-31 13F PROQR THRAPEUTICS N V SHS EURO Put 82,400 305 n/a n/a n/a
2022-05-16 2022-03-31 13F PROQR THRAPEUTICS N V SHS EURO Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-02-14 2021-12-31 13F PROQR THRAPEUTICS N V SHS EURO Put 22,800 -63.92 183 -65.41 n/a n/a n/a
2021-11-15 2021-09-30 13F PROQR THRAPEUTICS N V Cmn Put 63,200 114.24 529 165.83 n/a n/a n/a
2021-08-16 2021-06-30 13F PROQR THRAPEUTICS N V SHS EURO Put 29,500 -52.27 199 -51.34 n/a n/a n/a
2021-05-21 2021-03-31 13F/A PROQR THRAPEUTICS N V SHS EURO Put 61,800 281.48 409 501.47 n/a n/a n/a
2021-05-17 2021-03-31 13F PROQR THRAPEUTICS N V SHS EURO Put 61,800 409 n/a n/a n/a
2021-02-16 2020-12-31 13F PROQR THRAPEUTICS N V SHS EURO Put 16,200 -73.79 68 -83.37 n/a n/a n/a
2020-08-14 2020-06-30 13F PROQR THRAPEUTICS N V Cmn Put 0 -100.00 0 -100.00 n/a n/a n/a
2020-05-15 2020-03-31 13F PROQR THRAPEUTICS N V Cmn Put 20,500 113 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.